Prescription medicine
Fenofibrate Brand names: Antara, Lipofen, Tricor; first approved as Tricor (Micronized)
Fenofibrate (Tricor) is a prescription medicine with an FDA approval on record since 1993. FDA's NDC Directory lists it from 54 generic labelers, and pharmacies paid $0.103 per fenofibrate 160 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the fenofibrate FDA label on DailyMed (effective April 29, 2024, A-S Medication Solutions); the NDA 19304 record on Drugs@FDA; every fenofibrate label on DailyMed.
Highlights of the record
FDA label of April 29, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTRICOR is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ).
Forms and strengths
- 30 mg
- 40 mg
- 43 mg
- 48 mg
- 50 mg
- 54 mg
- 67 mg
- 90 mg
- 120 mg
- 130 mg
- 134 mg
- 145 mg
Tablet; film-coated tablet; capsule; coated tablet.
On the market
- Earliest approval on file
- December 31, 1993 Tricor (Micronized), Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 48 first April 9, 2002; 37 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 54 of which 54 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- May 31, 2033 Antara capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.103 per tablet Fenofibrate 160 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 8 since 2013 0 Class I among all firms' recalls; latest May 28, 2026; 2 more by firms not listed as its makers
- FAERS reports
- 35,248 through July 30, 2026
What is fenofibrate used for?
From the label: indications and usageTRICOR is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). […]
Conditions named in the indications of fenofibrate's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist.
Source: FDA drug label (Tricor), NDA021656 (Abbvie), as published by A-S Medication Solutions, effective April 29, 2024 (SPL set 84b2af1b-365e-4723-ac5f-bc826ec47772), via openFDA; the full label on DailyMed
Is there a generic for fenofibrate (Tricor)?
The FDA approved the first generic fenofibrate on April 9, 2002. 48 generic applications are approved; 37 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists fenofibrate from 54 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Tricor tablets; a patent listed only for Antara capsules runs to May 31, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1993 earliest approval on file
- 2002 first generic approved
- 2033 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for fenofibrate (Tricor)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.103 per Fenofibrate 160 mg tablet, down 14% from $0.121 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Fenofibrate 160 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Fenofibrate 120 mg tablet | Generic | $16.75 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $502.65 | +6% |
| Fenofibrate 130 mg capsule | Generic | $0.702 per capsule | $21.07 | -10% |
| Fenofibrate 134 mg capsule | Generic | $0.119 per capsule | $3.58 | -11% |
| Fenofibrate 145 mg tablet | Generic | $0.120 per tablet | $3.59 | +6% |
| Fenofibrate 150 mg capsule | Generic | $5.30 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $159.09 | -2% |
| Fenofibrate 160 mg tablet | Generic | $0.103 per tablet | $3.10 | -14% |
| Fenofibrate 200 mg capsule | Generic | $0.164 per capsule | $4.93 | -5% |
| Fenofibrate 40 mg tablet | Generic | $5.54 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $166.06 | -15% |
| Fenofibrate 43 mg capsule | Generic | $0.384 per capsule | $11.51 | +19% |
| Fenofibrate 48 mg tablet | Generic | $0.0794 per tablet | $2.38 | -13% |
| Fenofibrate 50 mg capsule | Generic | $2.56 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $76.79 | +0.9% |
| Fenofibrate 54 mg tablet | Generic | $0.0733 per tablet | $2.20 | -8% |
| Fenofibrate 67 mg capsule | Generic | $0.092 per capsule | $2.76 | -1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has fenofibrate been recalled?
The FDA's Enforcement Report lists 10 recalls naming fenofibrate since 2013: 0 Class I (the most serious), 5 Class II, 5 Class III; 2 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of fenofibrate and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 28, 2026 | Class II | Ajanta Pharma USA Inc | CGMP Deviations |
| March 13, 2025 | Class II | Glenmark Pharmaceuticals Inc., USA | CGMP Deviations |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| September 12, 2018 | Class III | Hetero Labs, Ltd. - Unit III | Presence of Foreign Tablet/Capsule: A foreign identified as Valacyclovir tablet 500 mg was co-mingled in a bottle containing Fenofibrate Tablets, USP 145 mg. |
| March 31, 2016 | Class III | Amerisource Health Services | Labeling: Incorrect or Missing Lot and/or Exp Date |
| March 17, 2016 | Class III | Impax Laboratories, Inc. | Labeling: Incorrect or Missing Lot and/or Exp. Date |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: FENOFIBRATE, Tablet, 54 mg may have potentially been mislabeled as the following drug: FAMCICLOVIR, Tablet, 500 mg, NDC 00093811956 … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: FENOFIBRATE, Tablet, 54 mg may have potentially been mislabeled as one of the following drugs: LUBIPROSTONE, Capsule, 24 MCG, NDC … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the fenofibrate label say about other medicines?
The fenofibrate label names 5 other medicines in its interaction, contraindication or warning sections. The labels of 10 other medicines name fenofibrate. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Colchicine | drug interactions | Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine. |
| Cyclosporine | drug interactions | Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration of renal … |
| Fenofibric acid | contraindications | … mothers [see Use in Specific Populations ( 8.2 ) ]. patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions ( 5.9 ) ]. |
| Gemfibrozil | warnings and precautions | Risks are increased during co-administration with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and patients with diabetes, renal failure, or hypothyroidism ( 5.3 ). |
| Tacrolimus | drug interactions | Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration of renal … |
Other labels that name fenofibrate
Source: FDA drug label (Tricor), NDA021656 (Abbvie), as published by A-S Medication Solutions, effective April 29, 2024 (SPL set 84b2af1b-365e-4723-ac5f-bc826ec47772), via openFDA; the full label on DailyMed
What do FAERS reports show for fenofibrate?
The FDA Adverse Event Reporting System holds 35,248 reports that list fenofibrate among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,766 are coded as a death and 12,310 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as fenofibrate?
15 other medicines are given the same way (oral) and in the same FDA class as fenofibrate or labeled mainly for the same use (high cholesterol), the same class first. High cholesterol lists all 25 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Gemfibrozil | High cholesterol | 27 labelers | $0.104 per tablet 600 mg tablet | A presentation being discontinued |
| Fenofibric acid | High cholesterol, High triglycerides | 7 labelers | $0.286 per capsule 135 mg capsule | No current entry |
| Atorvastatin | High cholesterol, High triglycerides | 61 labelers | $0.0228 per tablet 10 mg tablet | No current entry |
| Lovastatin | High cholesterol | 19 labelers | $0.0436 per tablet 20 mg tablet | No current entry |
| Pitavastatin | High cholesterol | 12 labelers | $0.954 per tablet 2 mg tablet | No current entry |
| Ezetimibe | High cholesterol | 23 labelers | $0.0667 per tablet 10 mg tablet | No current entry |
| Cholestyramine | High cholesterol | 15 labelers | $0.834 per packet Cholestyramine packet | No current entry |
| Colesevelam | High cholesterol | 15 labelers | $0.262 per tablet 625 mg tablet | No current entry |
Every medicine labeled for the same conditions as fenofibrate
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does fenofibrate compare with medicines for the same use?
7 side-by-side pages set fenofibrate beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to fenofibrate
- 15 medicines for the same use
- Other peroxisome proliferator receptor alpha agonists
- the pharmacologic class, with prices and generics
- Fenofibrate side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other